CANTARGIA AB [CBOE] overview

LUND, SE / ACCESS Newswire / June 17, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced that it has entered into a loan agreement of SEK 50 million with Fenja Capital II A/S, extending the company's financial runway well into 2026 and strengthening its position in consideration of strategic opportunities. "This non-dilutive facility immediately strengthens our financial position, balances near-term capital requirements and enables strategic...

Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels. Reflects high unmet medical need in metastatic PDAC. Facilitates further development of nadunolimab with more frequent FDA interactions and eligibility for Accelerated Approval and Priority Review. LUND, SE / ACCESS Newswire / June 11, 2025 / Cantargia (Cantargia AB (publ); NASDAQ Stockholm: CANTA), today announced that the U.S. Food and Drug Administration (FDA) has...

IL1RAP expression positively correlates with inflammatory markers in human atherosclerotic plaques. IL1RAP blocking antibodies inhibit endothelial activation and neutrophil adhesion induced by IL-1, IL-33 and IL-36. IL1RAP targeted therapy offers a novel strategy to mitigate vascular inflammation. LUND, SE / ACCESS Newswire / May 19, 2025 / Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced the publication of preclinical results from IL1RAP targeting antibodies in models of...

LUND, SWEDEN / ACCESS Newswire / May 15, 2025 / The Annual General Meeting of Cantargia (STO:CANTA) on May 15, 2025 resolved in accordance with the following: That no dividend would be paid. To discharge the board members and the CEO from liability with respect to their management of the company for 2024. That the board shall consist of five members with no deputies. That the remuneration to the members of the board shall amount to SEK 1,740,000 in total, whereby SEK 620,000 shall be distributed...

LUND, SE / ACCESS Newswire / May 13, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced its interim report for the first quarter of 2025. "The first quarter of 2025 has been rich in positive news for Cantargia. We continue to progress on all fronts, with strong news flow on all our projects and ongoing discussions regarding potential transactions that can be transformative for Cantargia. However, this has unfortunately been against a backdrop...

LUND, SE / ACCESS Newswire / May 12, 2025 / Cantargia (STO:CANTA) Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohort. Model confirms the predicted dosing regimen for phase 2, including subcutaneous (SC) dosing every 4-week. Safety of multiple SC dosing at a clinically relevant dose confirmed. Potent and long-lasting inhibitory effects on several key inflammatory biomarkers. Cantargia (Cantargia AB (publ); Nasdaq...

LUND, SE / ACCESS Newswire / May 6, 2025 / Cantargia (STO:CANTA) Results published in the peer-reviewed journal Investigational New Drugs Study in heavily pre-treated patients with solid tumor indications who had progressed on prior immune checkpoint inhibitors Median overall survival of 19.7 months, with greatest survival benefit in patients with high baseline levels of infiltrating immune cells in the tumor microenvironment Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the...

LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first quarter of 2025 on Tuesday, May 13, 2025, at 07:00 a.m. CEST. In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on May 13, at 3:00 p.m. CEST, where Cantargia's interim CEO, Damian Marron, and CFO, Patrik Renblad, will present Cantargia and...